Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
-
-
4-Aminopyridine (4-AP) (HB1073)
Description:Non-selective voltage gated K+ channel blocker
Purity:>99%
-
L-Ascorbic acid (HB1238)
Description:Antioxidant. Enhances iPSC generation and increases reprogramming efficiency. Supports mesenchymal stem cell proliferation.
Purity:>99%
-
(±)-Bay K 8644 (HB1209)
Description:L-type Ca2+ channel agonist. Aids iPSCs generation from Mouse embryonic fibroblasts.
Purity:>99%
-
-
ω-Conotoxin MVIIC (HB1219)
Description:N-, P- and Q-type voltage-dependent Ca2+ channel blocker
Purity:>99%
-
Hyperforin dicyclohexylammonium (HB3933)
Description:Selective TRPC6 channel activator and neurotransmitter re-uptake inhibitor
Purity:>97%
-
